Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

letetresgene autoleucel

Human autologous T lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, letetresgene autoleucel specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.
Synonym:autologous anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T lymphocytes GSK3377794
autologous T-cells expressing enhanced TCRs specific for NY-ESO-1/LAGE-1a GSK3377794
genetically engineered NY-ESO-1 specific [c259] T cells GSK3377794
genetically engineered NY-ESO-1/LAGE-1 specific (c259) T cells GSK3377794
NY-ESO-1c259 T cells GSK3377794
Search NCI's Drug Dictionary